MA55821A - Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression - Google Patents
Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépressionInfo
- Publication number
- MA55821A MA55821A MA055821A MA55821A MA55821A MA 55821 A MA55821 A MA 55821A MA 055821 A MA055821 A MA 055821A MA 55821 A MA55821 A MA 55821A MA 55821 A MA55821 A MA 55821A
- Authority
- MA
- Morocco
- Prior art keywords
- depression
- treatment
- ht2a antagonists
- ht2a
- antagonists
- Prior art date
Links
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 title 1
- 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 title 1
- 208000020401 Depressive disease Diseases 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19207578 | 2019-11-07 | ||
| PCT/EP2020/081357 WO2021089824A1 (fr) | 2019-11-07 | 2020-11-06 | Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA55821A true MA55821A (fr) | 2022-05-04 |
| MA55821B1 MA55821B1 (fr) | 2023-08-31 |
Family
ID=68502828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA55821A MA55821B1 (fr) | 2019-11-07 | 2020-11-06 | Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11246860B2 (fr) |
| EP (1) | EP3962601B1 (fr) |
| JP (1) | JP2023501275A (fr) |
| CN (1) | CN114761083B (fr) |
| AU (1) | AU2020379225A1 (fr) |
| BR (1) | BR112022008037A2 (fr) |
| CA (1) | CA3156513A1 (fr) |
| DK (1) | DK3962601T3 (fr) |
| ES (1) | ES2953926T3 (fr) |
| FI (1) | FI3962601T3 (fr) |
| HR (1) | HRP20230856T1 (fr) |
| HU (1) | HUE062369T2 (fr) |
| IL (1) | IL292585B2 (fr) |
| LT (1) | LT3962601T (fr) |
| MA (1) | MA55821B1 (fr) |
| MD (1) | MD3962601T2 (fr) |
| PL (1) | PL3962601T3 (fr) |
| PT (1) | PT3962601T (fr) |
| SI (1) | SI3962601T1 (fr) |
| WO (1) | WO2021089824A1 (fr) |
| ZA (1) | ZA202204809B (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11246860B2 (en) * | 2019-11-07 | 2022-02-15 | Lophora ApS | 5-HT2A agonists for use in treatment of depression |
| MX2022014605A (es) | 2020-05-19 | 2022-12-16 | Cybin Irl Ltd | Derivados de triptamina deuterada y metodos de uso. |
| CN117222623A (zh) * | 2021-05-06 | 2023-12-12 | 罗弗拉有限公司 | (s)-3-(2,5-二甲氧基-4-(三氟甲基)苯基)哌啶和(s)-3-(2-甲氧基-5-(甲硫基)-4-(三氟甲基)苯基)哌啶的酸加成盐，其特定多晶型物及其制备方法 |
| AU2022317782A1 (en) * | 2021-07-26 | 2024-01-25 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compounds and methods for treating 5-ht2 responsive conditions |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201314286D0 (en) | 2013-08-08 | 2013-09-25 | Takeda Pharmaceutical | Therapeutic Compounds |
| US11246860B2 (en) * | 2019-11-07 | 2022-02-15 | Lophora ApS | 5-HT2A agonists for use in treatment of depression |
-
2020
- 2020-11-05 US US17/090,457 patent/US11246860B2/en active Active
- 2020-11-06 CA CA3156513A patent/CA3156513A1/fr active Pending
- 2020-11-06 EP EP20808308.9A patent/EP3962601B1/fr active Active
- 2020-11-06 HU HUE20808308A patent/HUE062369T2/hu unknown
- 2020-11-06 JP JP2022525596A patent/JP2023501275A/ja active Pending
- 2020-11-06 IL IL292585A patent/IL292585B2/en unknown
- 2020-11-06 AU AU2020379225A patent/AU2020379225A1/en active Pending
- 2020-11-06 MA MA55821A patent/MA55821B1/fr unknown
- 2020-11-06 FI FIEP20808308.9T patent/FI3962601T3/fi active
- 2020-11-06 WO PCT/EP2020/081357 patent/WO2021089824A1/fr active Search and Examination
- 2020-11-06 ES ES20808308T patent/ES2953926T3/es active Active
- 2020-11-06 MD MDE20220277T patent/MD3962601T2/ro unknown
- 2020-11-06 PT PT208083089T patent/PT3962601T/pt unknown
- 2020-11-06 LT LTEPPCT/EP2020/081357T patent/LT3962601T/lt unknown
- 2020-11-06 CN CN202080078033.1A patent/CN114761083B/zh active Active
- 2020-11-06 PL PL20808308.9T patent/PL3962601T3/pl unknown
- 2020-11-06 SI SI202030239T patent/SI3962601T1/sl unknown
- 2020-11-06 BR BR112022008037A patent/BR112022008037A2/pt unknown
- 2020-11-06 DK DK20808308.9T patent/DK3962601T3/da active
- 2020-11-06 HR HRP20230856TT patent/HRP20230856T1/hr unknown
-
2021
- 2021-06-16 US US17/349,255 patent/US11633390B2/en active Active
- 2021-07-06 US US17/368,351 patent/US11642336B2/en active Active
-
2022
- 2022-04-29 ZA ZA2022/04809A patent/ZA202204809B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US11642336B2 (en) | 2023-05-09 |
| MD3962601T2 (ro) | 2023-10-31 |
| US11633390B2 (en) | 2023-04-25 |
| HRP20230856T1 (hr) | 2023-11-10 |
| AU2020379225A1 (en) | 2022-05-26 |
| PT3962601T (pt) | 2023-08-28 |
| DK3962601T3 (da) | 2023-09-04 |
| WO2021089824A1 (fr) | 2021-05-14 |
| US11246860B2 (en) | 2022-02-15 |
| ES2953926T3 (es) | 2023-11-17 |
| IL292585A (en) | 2022-06-01 |
| US20210137908A1 (en) | 2021-05-13 |
| FI3962601T3 (fi) | 2023-08-09 |
| JP2023501275A (ja) | 2023-01-18 |
| ZA202204809B (en) | 2022-11-30 |
| MA55821B1 (fr) | 2023-08-31 |
| IL292585B2 (en) | 2023-08-01 |
| EP3962601A1 (fr) | 2022-03-09 |
| EP3962601B1 (fr) | 2023-05-31 |
| CN114761083B (zh) | 2024-02-13 |
| IL292585B1 (en) | 2023-04-01 |
| PL3962601T3 (pl) | 2023-10-09 |
| CA3156513A1 (fr) | 2021-05-14 |
| US20220062257A1 (en) | 2022-03-03 |
| HUE062369T2 (hu) | 2023-10-28 |
| BR112022008037A2 (pt) | 2022-07-12 |
| LT3962601T (lt) | 2023-09-11 |
| CN114761083A (zh) | 2022-07-15 |
| SI3962601T1 (sl) | 2023-10-30 |
| US20210330658A1 (en) | 2021-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA55821A (fr) | Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression | |
| MA49458A (fr) | Composés interagissant avec la superfamille ras destinés à être utilisés dans le traitement de cancers, de maladies inflammatoires, de rasopathies et de maladies fibrotiques | |
| MA51200A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA49682A (fr) | Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp | |
| MA49760A (fr) | Mavacamten destiné à être utilisé dans le traitement de la cardiomyopathie hypertrophique | |
| MA45073A (fr) | Nouveaux peptides, combinaison de peptides et d'échafaudages destinés à être utilisés dans le traitement immunothérapeutique de divers cancers | |
| FR24C1010I1 (fr) | Modulateurs des récepteurs p2x3 et p2x2/3 de diaminopyrimidine destinés à être utilisés dans le traitement de la toux | |
| MA51032A (fr) | Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée | |
| MA47688A (fr) | Compositions utiles dans le traitement de l'amyotrophie spinale | |
| MA52245A (fr) | Promédicaments d'antagonistes de c5ar bicycliques fusionnés | |
| MA44676A (fr) | Compositions de disulfure de sélénium destinées à être utilisées dans le traitement du dysfonctionnement de la glande de meibomius | |
| DK3681500T3 (da) | Anvendelse af pilocarpinhydrochlorid til behandling af presbyopi | |
| MA50905A (fr) | Composés et compositions pharmaceutiques de ceux-ci destinés à être utilisés dans le traitement de maladies fibrotiques | |
| MA43817A (fr) | Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2 | |
| MA54515A (fr) | Dérivés de quinoléine destinés à être utilisés dans le traitement de maladies inflammatoires | |
| MA50233A (fr) | Mic-1 et glp-1 destinés à être utilisés dans le traitement de l'obésité | |
| MA49248A (fr) | Inhibiteurs de fgfr2 utilisés dans le traitement du cholangiocarcinome | |
| MA46608A (fr) | Formulation liposomale destinée à être utilisée dans le traitement du cancer | |
| IT201600121601A1 (it) | Composizione orale per il trattamento del reflusso gastroesofageo e del reflusso laringo-faringeo | |
| MA49131A (fr) | Utilisation d'antagonistes de klk5 pour le traitement d'une maladie | |
| MA47111A (fr) | Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer | |
| MA55200A (fr) | Composés utiles dans la thérapie du vih | |
| MA49524A (fr) | Compositions d'antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression | |
| MA53280A (fr) | Composés utiles dans la thérapie du vih | |
| MA43825A (fr) | Schémas posologiques pour le traitement d'infections fongiques |